In addition, we demonstrated that AZD2281 induces growth inhibition in BRCA wild-type breast cancer cell lines with BRCA1 allelic loss, indicating that breast cancer patients with BRCA1 allelic loss may benefit from PARP inhibitors. Here, BRCA1 is linked to breast carcinoma.